According to the WHO 2021 classification, IDH-wildtype astrocytic glioma is diagnosed as GBM, i.e., molecular GBM, if at least one of the following molecular features is present: TERTp mutation, EGFR amplification, or the combined whole chromosome 7 gain and whole chromosome 10 loss (chr 7+/10−). This evidence concerns the gene IDH2 and glioblastoma.